Research use only. Nothing on this page is medical advice, and no bioregulator peptide is FDA-approved.
Bioregulator peptides are short peptides developed by Vladimir Khavinson’s institute in St. Petersburg. Some are extracts from animal organs, and some are lab-made chains of 2 to 4 amino acids (1).
What the evidence shows:
- Claimed benefits: longer lifespan and fewer tumors in rodents, and human benefits reported by the institute (2, 3)
- The weakness: most evidence comes from one research group, and reviews say independent clinical validation is still missing (4)
Jump to the organ map, the evidence, safety or where to buy.
- Developer
- Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology (1)
- Two kinds
- Natural extracts from animal organs, and synthetic peptides of 2 to 4 amino acids (1)
- Claimed mechanism
- Short peptides enter the nucleus, bind histones and DNA, and change gene activity (5)
- Best human evidence
- Reports from the developers’ own institute. Reviews call independent validation limited (4)
- FDA status
- None approved. Epitalon acetate is named in HHS’s 28 Oct 2026 policy for licensed pharmacies only (6)
- Forms sold online
- Vials and capsules labeled research chemicals or supplements
What are bioregulator peptides?
Khavinson’s group describes two kinds. Natural bioregulators are peptide complexes extracted from animal organs, such as Thymalin from the thymus and epithalamin from the pineal gland. Synthetic ones are short peptides built from amino acids, such as Epitalon, Vilon and Thymogen (1). The group names each one after the organ it is meant to target.
Sellers call the synthetic peptides cytogens and the extracts cytomaxes (7). Our Khavinson peptides guide has the full list with sequences. For a side-by-side with regular peptide drugs, see bioregulators vs regular peptides.
Which bioregulator targets which organ?
These targets are the developers’ claims. The linked guides hold the sources.
How to read the table. Limited: small human reports from the developers’ network. Animals, Cells: lab work only. Warning: a harmful signal was reported.
| Claimed target | Peptide and sequence | Best evidence |
|---|---|---|
| 1Pineal gland | Epitalon, AEDG (Ala-Glu-Asp-Gly) | LimitedSmall biomarker studies, no adequately powered trial (8) |
| 2Brain | Pinealon, EDR. Cortagen, AEDP | LimitedPinealon has small reports. Cortagen has animal work only |
| 3Thymus and immune system | Vilon, KE. Thymogen, EW | WarningVilon raised mammary cancer in one mouse model (9). Thymogen failed a phase III as IM862 |
| 4Blood vessels | Vesugen, KED | LimitedOne small human report |
| 5Heart | Cardiogen, AEDR | CellsCell culture and rat heart tissue |
| 6Lungs | Bronchogen, AEDL. Chonluten, EDG | CellsCell studies (5, 10) |
| 7Pancreas | Pancragen, KEDW | AnimalsOld rhesus monkey and rat studies |
| 8Liver and kidney | Livagen, KEDA. Ovagen, EDL | AnimalsAnimal injury models |
| 9Cartilage | Cartalax, AED | AnimalsRat kidney and cell studies |
| 10Prostate | Prostamax, KEDP | CellsRat prostate tissue and lymphocytes |
| 11Testes | Testagen, KEDG | AnimalsBird and cell studies |
Sequences follow the developers’ 2021 review (5). Capsules sold for the adrenals, muscle or other organs are typically the natural extracts described above. They have no single sequence to test, and we found no published trial for them in our sources.
Do bioregulator peptides work?
Independent evidence hasn’t shown that they do. Reviews describe promising preclinical results and limited clinical data, with long-term safety and dosing still open (4).
How to read the table. Limited: human reports from the developers’ network. Mice, Cells: lab work only. Review: a summary of other studies. Warning: a harmful signal was reported.
| Study | Model | What it reported | Watch-out |
|---|---|---|---|
| People | |||
| 1Khavinson and Morozov, 2003Clinical report, controls not described | 266 older people followed 6 to 8 years, Thymalin and epithalamin extracts | LimitedMortality was 1.6 to 2.1 times lower with one extract, 2.5 times with both, and 4.1 times in a subgroup given both for 6 years (3) | Extracts, not synthetic peptides. Written by the institute’s own leaders |
| 2Trofimova, 2020Book chapter on cytogens | People with degenerative retinal disease | LimitedReports visual function improved in 80% of patients across 30 years of work (7) | Developer group. The abstract gives no controls or sample size |
| 3Yakovlev, 2024Russian review | Prostatex and Prostateks Plus in prostatitis and BPH | ReviewConcludes clinical studies show high effectiveness in chronic prostatitis and BPH (11) | Reviews domestic drugs. The abstract names no trial sizes |
| 4Kim, 2023Review of Russian studies | Intranasal peptide use under hypoxia, heat and Arctic conditions | ReviewReports short courses raised tolerance of adverse conditions, with delayed effects (12) | No effect sizes in the abstract |
| Animals | |||
| 5Anisimov, 2010Review of the author’s own work | Rodents given peptide preparations long term | ReviewMean lifespan rose 20 to 40% with some preparations, and tumor development was suppressed (2) | Epitalon alone left mean lifespan unchanged in the study below |
| 6Anisimov, 2003Controlled mouse study | Female SHR mice given epitalon | MiceMean lifespan was unchanged. The last 10% of survivors lived 13.3% longer, maximum lifespan rose 12.3%, and leukemia fell 6-fold (13) | One peptide, one mouse strain, the developer’s lab |
| 7Anisimov, 2002Controlled mouse study | HER-2/neu mice given epitalon or Vilon | WarningEpitalon reduced tumor number and size. Vilon raised mammary cancer incidence and shortened tumor latency (9) | Shows that results differ between peptides |
| Cells and mechanism | |||
| 8Khavinson, 2021Review by the developers | DNA and histone binding of short peptides | ReviewPeptides of 2 to 7 residues enter nuclei. EDR, AEDG, AEDL, KEDW, AEDR and KEDG bind histones H1, H2b, H3 and H4 (5) | The group reviews its own studies. Untested in people |
| 9Avolio, 2022Cell study of five peptides | THP-1 human monocyte cells | CellsEpitalon, Vilon, Thymogen, Thymalin and Chonluten lowered TNF and IL-6 after a bacterial trigger (10) | A leukemia cell line, in vitro only |
| Independent reviews | |||
| 10Mavrych, 2026Narrative review of peptides in aging | Peptides studied for healthy aging, epitalon among them | ReviewNon-approved peptides show promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation (4) | Covers peptides generally, not only bioregulators |
| 11Jain, 2026Narrative review | Epitalon and epithalamin | ReviewHuman data are small biomarker studies plus one older controlled study. No adequately powered randomized trial exists (8) | Covers epitalon only |
The human reports come from the group that makes the peptides. Independent reviews rate the evidence as limited. A result for one bioregulator also doesn’t carry over to another: epitalon alone left mean lifespan unchanged in mice, and Vilon raised cancer (9, 13).
How are bioregulator peptides supposed to work?
The institute proposes that short peptides enter cell nuclei, bind histones and DNA, and open tightly packed chromatin so silenced genes can switch on (5). That idea rests on modeling and cell studies from the same group. Nobody has shown it in people.
Are bioregulator peptides safe?
- No long-term human safety data exist (4).
- Vilon raised mammary cancer in one mouse model (9).
- Epitalon lengthened telomeres in breast cancer cells as well as normal cells (14).
- Extracts are mixtures, so their contents are harder to verify than a single peptide.
Cancer is the main theoretical concern, so a cancer history is the clearest reason to avoid them.
Are bioregulator peptides legal?
None is FDA-approved (15). Russia registered Thymogen as a drug under certificate P N002408/01 in 2009 (16).
An HHS interim policy of 28 October 2026 lets state-licensed pharmacies compound six named peptides on prescription, and epitalon acetate is one of them. It excludes products sold as research chemicals or dietary supplements (6). So the vials and capsules sold online sit outside it. A research-use-only label is a sales category and tells you nothing about the contents.
Bioregulator peptide dosage
We don’t list doses or course schedules. Reviews name optimal dosing as an open knowledge gap (4), and the schedules on seller pages don’t trace to independent trials.
Where to buy bioregulator peptides
SwissChems sells the widest range we found: 11 Khavinson-type peptides as 20 mg vials (17). Epitalon has several sellers, and our buy epitalon guide compares their lab reports.
SwissChems bioregulator range
Eleven peptides · research use only
- Pinealon, Cortagen, Cardiogen, Livagen, Ovagen, Cartalax, Prostamax, Testagen, Bronchogen, Pancragen and Thymogen
- Free US shipping over $100, same-day US dispatch before 12 PM EST
- 30-day returns on unopened products
Extract capsules have no defined sequence, so identity data is harder to read than for a single-peptide vial.
How do you check a bioregulator product?
- The exact name and sequence on the label and the report, for example AEDG for epitalon.
- Identity by mass spectrometry, not only a purity percentage.
- A lot number on the report that matches your vial, from a lab you can look up.
- The form. Some peptides exist as an amide and a free acid, as pancragen does.
Our guide to verifying a peptide COA explains each line, and best peptide vendors compares sellers by their lab reports. Keep researching: the Khavinson peptides guide, Thymogen, Vilon and the full list of peptides.
Bioregulator peptides FAQ
What are bioregulator peptides?
Bioregulator peptides are short peptides developed by Vladimir Khavinson’s institute in St. Petersburg. Some are extracts from animal organs, and some are synthetic chains of 2 to 4 amino acids. They are named after the organ they are meant to target.
Do bioregulator peptides work?
Independent evidence hasn’t shown that they do. Rodent studies and reports from the developers’ institute describe benefits, but reviews call the human evidence limited and say independent validation is still missing.
What is the difference between bioregulators and regular peptides?
Bioregulators are proposed to act inside the cell nucleus on DNA and histones. That mechanism comes from the developers’ group and hasn’t been shown in people. Each peptide has to be judged on its own evidence.
What is the difference between natural and synthetic bioregulators?
Natural bioregulators are extracts from animal organs, such as Thymalin and epithalamin. Synthetic ones are lab-made short peptides with a defined sequence, such as Epitalon, Vilon and Thymogen.
Are bioregulator peptides safe?
No long-term human safety data exist. Vilon raised mammary cancer in one mouse model, and epitalon lengthened telomeres in breast cancer cells. A cancer history is the clearest reason to avoid them.
Are bioregulator peptides FDA approved or legal?
None is FDA-approved. An HHS policy from 28 October 2026 covers epitalon acetate only when a licensed pharmacy compounds it on prescription. It excludes products sold as research chemicals or supplements.
What are cytogens and cytomaxes?
Sellers use cytogens for the synthetic short peptides and cytomaxes for the natural organ extracts.
What is the bioregulator peptide dosage?
No independently tested dose exists, and reviews call dosing an open knowledge gap. We don’t list doses or course schedules.
Where can you buy bioregulator peptides?
SwissChems sells 11 Khavinson-type peptides as 20 mg vials, and several sellers list epitalon. Match the lot number on your vial to a lab report before you rely on it.
Sources
Show references (17)Hide references
- Khavinson V, et al. Peptide medicines: past, present, future. Klin Med (Mosk) 2020. Source
- Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology 2010. Source
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003. Source
- Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. Source
- Khavinson V, et al. Peptide regulation of gene expression: a systematic review. Molecules 2021. Source
- BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 28 October 2026. Source
- Trofimova S, et al. Results of the clinical study of short peptides (cytogens) in ophthalmology. Springer chapter 2020. Source
- Jain A, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci 2026. Source
- Anisimov VN, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2002. Source
- Avolio F, et al. Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int J Mol Sci 2022. Source
- Yakovlev AV, et al. Efficacy and safety of bioregulatory peptides in the treatment of prostate diseases: a review. Consilium Medicum 2024. Source
- Kim AE, et al. Study of the influence of peptide bioregulators on the resistance of the organism to adverse effects. Reviews on Clinical Pharmacology and Drug Therapy 2023. Source
- Anisimov VN, et al. Effect of epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003. Source
- Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025;26:178. Source
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content dated 22 April 2026). Source
- Deigin V, et al. The first reciprocal activities of chiral peptide pharmaceuticals: Thymogen and Thymodepressin, as examples. Int J Mol Sci 2024. Source
- SwissChems. Bioregulator product category (11 products, 20 mg vials). Source
